

Letter to the Editor

Light After Armageddon: Enhancing Cardiovascular Care through Emerging Technologies and Patient-Centric Approaches

Damien Gruson^{1,2,3}; Chiara Peranio⁴; Sergio Bernardini⁵, Aistė Štaraitė⁶, Mikki Koo⁷, Mike Coyle⁷, Bryan Shannon⁸, David Luu⁹, Ed Harding¹⁰, Tuğba Kemalöglu Öz^{11,12}

¹Department of Laboratory Medicine, Cliniques Universitaires St-Luc, Brussels, Belgium and Université Catholique de Louvain, Brussels, Belgium

²Pôle de recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium

³IFCC Division on Emerging Technologies

⁴Communication and digital Marketing, University Mercatorum, Roma, Italy

⁵ Department. of Experimental Medicine, University of Tor Vergata, Roma, Italy

⁶Global Heart Hub, The International Alliance of Heart Patient Organisations

⁷Roche Diagnostics International, Switzerland

⁸ParadigmDx, Carlsbad, California, USA

⁹The Heart Fund, Paris, France

¹⁰Health Policy Partnership, London, United Kingdom

¹¹Alice Springs Hospital, Alice Springs, Australia

¹²Flinders University, Faculty of Medicine, SA, Australia

Article Info

Author of correspondence:

Damien Gruson

Department of Laboratory Medicine, Cliniques Universitaires St-Luc et Université Catholique de Louvain

E-mail: damien.gruson@uclouvain.be

Telephone: +32 (0)2 764 67 47

Fax number: +32 (0)2 764 69 30

Address:

Cliniques Universitaires St-Luc et Université Catholique de Louvain, 10 Avenue Hippocrate, Brussels, B-1200, Belgium

Keywords

Cardiovascular diseases, prevention, emerging technologies, artificial intelligence, biomarkers

Abstract

To the Editor,

In the wake of a global healthcare crisis that shook the very foundations of our medical systems, a metaphorical ‘Armageddon’, the world stands at a critical juncture. This juncture, while marked by challenges, also opens a doorway to unprecedented opportunities, particularly in the realm of cardiovascular care. The Covid pandemic was a first trigger of reflection with an article entitled “COVID-19: Armageddon before light” [1]. The “Light After Armageddon” initiative emerges as a beacon of hope, embodying a collective endeavor to navigate through the storm and lead cardiovascular healthcare into a new era marked by innovation, resilience, and patient-centred care. The term ‘Armageddon’, often evoking images of final battles or cataclysmic destruction, in this context, symbolizes a turning point—a crisis that demands a transformative approach in healthcare. This crisis has underscored the fragility of our health systems, revealing vulnerabilities in dealing with cardiovascular diseases (CVDs), the leading cause of mortality globally [2]. However, it has also highlighted the indomitable spirit of the medical community and the infinite potential of emerging technologies to revolutionize healthcare [3,4]. CVD, encompassing a range of conditions affecting the heart and cardiovascular system, have long posed significant challenges to healthcare providers and patients alike. Traditional approaches, while effective to a degree, often fall short in addressing the complexities of CVDs, especially in early detection and personalized treatment. The advent of the ‘Armageddon’ has acted as a catalyst, accelerating the integration of innovative solutions into cardiovascular care. These technologies,

once the realm of science fiction, are now at the forefront of a healthcare revolution, offering new pathways to diagnose, treat, and manage CVDs more efficiently and effectively than ever before [5-7]. Furthermore, emerging technologies are essential to address the increasing number of high-risk individuals and to tackle new risk factors that continue to emerge in the field of cardiovascular health [8]. These advancements are also crucial in managing and mitigating the risks posed by novel environmental and genetic factors influencing cardiovascular diseases [9].

The “Light After Armageddon” initiative stands as a sharing a vision to the power of innovation and collaboration in the face of adversity. By harnessing the capabilities of emerging technologies, the project seeks to pave the way for a future where CVD care is not only more accessible and equitable but also more attuned to the needs and expectations of patients. Through the feedback of the participants, we explored the transformative impact of these technologies on cardiovascular healthcare. We examined the successes and challenges, the stories of hope and the visions for the future, shared by leading experts and patient advocates. Through their insights and contributions, we pieced together a mosaic of possibilities, illustrating how the post-’Armageddon’ era could herald a new dawn for cardiovascular care—one where every heartbeat matters, and no patient is left behind.

First, we began by identifying a diverse group of expert stakeholders, including cardiologists, healthcare policymakers, technology developers, and patient advocates. Through a series of contributions, we gathered insights and expectations concerning new technological solutions. This initiative framework ensured a holistic understanding of emerging technologies’ role in enhancing patient outcomes, optimizing clinical workflows, and fostering a patient-centric approach in the new era of cardiovascular healthcare. The results of the collected insights unveiled compelling evidence of the transformative power of emerging technologies in cardiovascular care. The diverse contributions received painted a vivid picture of a healthcare landscape on the cusp of revolution, driven by the integration of digital innovation and patient-centric approaches.

From the contributions, a consensus emerged on the pivotal role of artificial intelligence (AI) in revolutionizing diagnostics and treatment strategies. AI’s ability to analyse large datasets has led to more accurate and rapid diagnosis, tailoring treatment plans to individual patient profiles, and significantly improving outcomes. It has also allowed for portable, AI-enhanced devices that can be used by allied healthcare professionals, such as in echocardiogram. In this fashion, it promises to dramatically expand the reach of diagnostic services across our communities and remove the unacceptable burden of adverse outcomes experienced by symptomatic patients on waiting lists for diagnosis and therefore the onset of therapies. New laboratory digital platform that integrates clinical decision support tools with hospital IT systems, highlight how such technologies

enhance the precision and efficiency of cardiac care.


AI is also at the forefront of personalized care. Shifting from cure to care means that individuals with enhanced cardiovascular risks could undergo proactive treatment, even in asymptomatic cases. Such an approach promises to catch potential diseases before they manifest into symptomatic and possibly severe conditions, thereby improving outcomes and reducing long-term healthcare costs. In addition to traditional risk factors, emerging biomarkers and novel genetic markers are showing promise in identifying at-risk individuals more accurately. Incorporating these markers into routine screenings could significantly enhance early detection efforts, ultimately reducing the waiting lists for cardiovascular care by identifying and managing high-risk individuals before they develop severe symptoms. The integration of advanced biomarkers and AI algorithms in routine diagnostics can streamline patient prioritization. By accurately identifying those at highest risk, healthcare providers can start earlier the right treatment and optimize resource allocation, ensuring that high-risk patients receive timely interventions while reducing unnecessary tests and procedures for those at lower risk.

Telemedicine emerged as another crucial technological advance, breaking down geographical barriers to care. Contributions illustrated the role of telemedicine’s role in facilitating remote patient monitoring, virtual consultations, and continuous care delivery, especially in underserved areas. Telemedicine can also trigger more easily remote multidisciplinary care for patient with cardiovascular. This was particularly relevant in the current global health climate, where access to in-person healthcare services has been challenged.

Wearable devices and mobile health technologies were identified as key drivers in shifting the focus from treatment to prevention. By enabling continuous monitoring of vital signs and cardiac health indicators, these devices empower patients to play an active role in managing their health. This proactive approach highlights the potential for wearable technologies to alert patients and healthcare providers to early signs of CVD, facilitating timely intervention. Specialists in laboratory medicine should be actively engage in the validation and evaluation of this new generation of wearables and sensors.

The potential of 3D printing in cardiology was another significant perspective. It has revolutionized preoperative planning and patient education by allowing for the creation of patient-specific anatomical models. This technology enhances surgical precision and patient understanding of their condition, leading to improved surgical outcomes and patient satisfaction. Even if in the opinions received 3D printing directly relates to surgical applications, its integration within the lab setting for creating diagnostic tools and educational materials justifies its inclusion. The figure illustrates these game-changing technologies in cardiovascular care

Figure 1: Game-Changing Technologies Redefining Cardiovascular Care.



Lastly, the project underscored the importance of equitable access to these emerging technologies. Despite the promising advancements, disparities in technology access and healthcare delivery remain a critical challenge. Contributors emphasized the need for policies and frameworks that ensure all patients, regardless of geographical or socio-economic status, benefit from these innovations.

The collective insights gleaned from the “Light After Armageddon” initiative not only underscore the transformative potential of emerging technologies in cardiovascular care but also chart a course for navigating the complexities of their integration into existing healthcare frameworks. As we distilled the wealth of contributions from experts across the spectrum of cardiovascular health, a multifaceted narrative emerges—one that balances the optimism of technological advancements with the pragmatism required for their effective deployment.

Central to this discussion is the acknowledgment of artificial intelligence (AI) as a linchpin in the evolution of cardiovascular diagnostics and treatment. AI’s capacity to sift through and make sense of vast amounts of data heralds a new era of precision medicine, where treatments are not just patient-centred but are intricately tailored to the individual’s unique physiological and genetic makeup.

Telemedicine and wearable devices stand out as technologies that democratize access to cardiovascular care, bridging the divide between remote or underserved populations and high-quality healthcare services. The pandemic has accelerated the adoption of these technologies, revealing a path forward where healthcare can be both ubiquitous and tailored. Yet, the

widespread adoption of telemedicine and wearable technologies necessitates a robust digital infrastructure, underpinned by policies that protect patient data privacy while enabling seamless data sharing between patients and healthcare providers.

The advent of 3D printing in cardiology, offering personalized preoperative planning and education, exemplifies the tangible benefits of emerging technologies. However, to harness these benefits broadly, healthcare systems must navigate the challenges of cost, accessibility, and clinician training in the use of such advanced technologies.

Equity in access to these innovations emerges as a critical theme in the discourse on the future of cardiovascular care. The contributions highlight a significant gap between the promise of technological advancements and their accessibility to all segments of the population. Addressing this gap requires concerted efforts from policymakers, healthcare providers, and the tech community to devise strategies that ensure these life-saving technologies benefit everyone, irrespective of their socio-economic status or geographic location.

In conclusion, the “Light After Armageddon” initiative underscores a future where emerging technologies could potentially redefine cardiovascular care. However, realizing this future demands a collaborative approach that considers the ethical, logistical, and economic facets of technology integration into healthcare. It calls for a paradigm shift towards a more resilient, equitable, and patient-centric healthcare ecosystem, where the advancements heralded by our current technological renaissance are within reach of every heart that beats. As a key element of the diagnosis and monitoring of cardiovascular

diseases, specialists in laboratory medicine and clinical laboratories will be important parts and players for this future. As Charles Darwin aptly noted, “It is not the strongest of the species that survive, nor the most intelligent, but the one most responsive to change.”

References

1. COVID-19: Armageddon before Light? - PubMed <https://pubmed.ncbi.nlm.nih.gov/32549877/>
2. Deaths from cardiovascular disease surged 60% globally over the last 30 years: Report - World Heart <https://world-heart-federation.org/news/deaths-from-cardiovascular-disease-surged-60-globally-over-the-last-30-years-report/>
3. Greaves RF, Kricka L, Gruson D, Martin H, Ferrari M, Bernardini S. Emerging technology: A definition for laboratory medicine. *Clin Chem Lab Med* 2022;61(1):33–36. <https://www.degruyter.com/document/doi/10.1515/cclm-2022-0929/html>
4. Gruson D, Kemaloglu Öz T. Emerging Technologies in Healthcare and Laboratory Medicine: Trends and Need for a Roadmap to Sustainable Implementation. *Balkan Med J.* 2024;41(2):85–86. <http://balkanmedicaljournal.org/abstract.php?lang=en&id=2572>
5. Gill SK, Karwath A, Uh HW, Cardoso VR, Gu Z, Barsky A, et al. Artificial intelligence to enhance clinical value across the spectrum of cardiovascular healthcare. *Eur Heart J* 2023;44(9):713–725. <https://dx.doi.org/10.1093/eurheartj/ehac758>
6. Gruson D, Greaves R, Dabla P, Bernardini S, Gouget B, Öz TK. A new door to a different world: opportunities from the metaverse and the raise of meta-medical laboratories. *Clin Chem Lab Med* 2023;61(9):1567–1571. <https://www.degruyter.com/document/doi/10.1515/cclm-2023-0108/html>
7. Innovation: early diagnosis in community settings - The Heart Failure Policy Network | The Heart Failure Policy Network. <https://www.hfpolicynetwork.org/project/innovation-early-diagnosis-in-community-settings/>
8. Pop-Busui R, Januzzi JL, Bruemmer D, Butalia S, Green JB, Horton WB, et al. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. *Diabetes Care* 2022;45(7):1670–1690. <https://dx.doi.org/10.2337/dci22-0014>
9. Montone RA, Camilli M, Calvieri C, Magnani G, Bonanni A, Bhatt DL, et al. Exposome in ischaemic heart disease: beyond traditional risk factors. *Eur Heart J* 2024;45(6):419–438. <https://dx.doi.org/10.1093/eurheartj/ehae001>